CD33, commonly expressed in a subpopulation in KMT2A-rearranged infant ALL [36–38], serves as an important immunophenotypic marker for the characterization of pediatric acute myeloid leukemia (AML) by EuroFlow [39–42] and has been exploited as a therapeutic target for AML. The gene discussed is CD33; the disease is acute myeloid leukemia.